Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,132 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: Metastatic Colorectal Cancer
Interventions: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 26
States / cities: Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Palovarotene, Placebo; Drug
Lead sponsor: Clementia Pharmaceuticals Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: San Francisco, California • Philadelphia, Pennsylvania

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more

Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung
Interventions: SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, carboplatin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 18 more

Conditions: Pre-diabetes, Overweight, Obese
Interventions: Filipinos Fit and Trim Weight Loss Program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 24 Years to 80 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Magnetic Resonance Imaging Simulation; Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adenocarcinoma
Interventions: PEGPH20, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Andrew Ko; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Venous Thrombosis
Interventions: Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 5,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 73
States / cities: Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more

Conditions: Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Alzheimers, Frontotemporal Dementia
Interventions: Care Ecosystem; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1,227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Torrance, California • Denver, Colorado + 3 more

Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions: Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ); Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 25 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • Seattle, Washington

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 130
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more

Conditions: Novel Influenza A, H1N1, Influenza
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 86
States / cities: Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 52 more

Conditions: Mindfulness Based Stress Reduction, Caregiver Burnout, Caregiver Stress Syndrome, Dementia, Dementia Frontal, Frontotemporal Dementia, Frontotemporal Lobar Degeneration
Interventions: Mindfulness-Based Stress Reduction, Self-Guided Mindfulness eCourse; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Apalutamide, LHRH Analogue, Abiraterone Acetate, Prednisone; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 69
States / cities: Phoenix, Arizona • Chula Vista, California • Duarte, California + 58 more

Conditions: Acute Myeloid Leukemia
Interventions: AMV564, AMV564 in combination with pembrolizumab; Biological · Combination Product
Lead sponsor: Amphivena Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Pharmacodynamic
Interventions: betaine hydrochloride, Rabeprazole; Dietary Supplement · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 59 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C Virus Infection
Interventions: Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more

Conditions: Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm
Interventions: Fitbit, Apple HealthKit-based devices; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Kaposi's Sarcoma
Interventions: Maraviroc; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Refractory Angina
Interventions: Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry; Device · Other
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 72
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more

Conditions: Biliary Tract Carcinoma
Interventions: Pembrolizumab, Gemcitabine, Cisplatin, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 18
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Modafinil; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 23
States / cities: Little Rock, Arkansas • Irvine, California • San Francisco, California + 20 more

Conditions: Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Acute Leukemias
Interventions: EPZ-5676; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 5 more

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Search by objective public record fields.

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects

A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis

A Study of SEA-CD40 Given With Other Drugs in Cancers

Fit and Trim for Diabetes Prevention

Magnetic Resonance Imaging in Radiotherapy for Breast Cancer

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

The Care Ecosystem Consortium Effectiveness Study

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Novel Influenza A (H1N1) Surveillance Registry

Mindfulness-Based Stress Reduction in Dementia Caregivers

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Study of AMV564 in Patients With AML

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Wearable Activity Tracking to Curb Hospitalizations

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment

A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia